NDATOPICALSPONGE
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SCRUBTEAM SURGICAL SPONGEBRUSH is a topical hexachlorophene-based surgical sponge approved in 1977 for treating staphylococcal infections. It is a non-antibiotic antimicrobial indicated for surgical site preparation and infection control in perioperative settings. The product acts as a topical antiseptic to reduce bacterial colonization on skin surfaces.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30); team focus is likely on defending market share and managing transition as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SCRUBTEAM offers limited growth upside given LOE-approaching status and zero linked job openings; career value lies in defending market position, managing payer relationships, and learning cost-containment strategy in a consolidating segment. This role suits professionals comfortable with mature-product stewardship rather than launch or growth trajectories.
Brand Manager
Worked on SCRUBTEAM SURGICAL SPONGEBRUSH at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.